Skip to content

MiRNAs Evaluate the Prognosis of Sepsis

miRNA in the Evaluation of the Value of Sepsis Prognosis Prospective Observational Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01207531
Acronym
METPS
Enrollment
100
Registered
2010-09-23
Start date
2010-07-31
Completion date
2011-04-30
Last updated
2010-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

sepsis, miRNA

Brief summary

Sepsis is a common cause of death in intensive care unit, timely and accurate diagnosis and treatment directly affect the survival rate. MiRNA is a post-transcriptional small RNA which regulate mRNA expression. The present study was designed to screen several miRNA by microarray which evaluate the sepsis prognosis in order to be a new target for the treatment of sepsis.

Detailed description

The study is a non-intervention, prospective observational study. Purpose of this sudy is to screening several miRNAs by microarray which can evaluate the prognosis of sepsis . We will collect serum samples from patients with sepsis in SICU, RICU and EICU of 301 Hospital since September 2009 , and then use the chip and qRT-PCR to Screen miRNAs which can evaluate the prognosis of sepsis, and statistical analysis the miRNAS expression correlation with SOFA score.

Interventions

None listed

Sponsors

Chinese PLA General Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Clinical diagnosis of sepsis * Patients who agree with the study

Exclusion criteria

* Aged \<18 years; * Into the group who died within 24 hours; * Agranulocytosis (\<0.5 × 109 / L); * Combined HIV infection.

Design outcomes

Primary

MeasureTime frame
all cause mortality28days after admited in ICU

Countries

China

Contacts

Primary ContactHuijuan Wang, master
wanghuijuan301@gmail.com+86 13466791738

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026